UNSPSC 51283939: Mafenide hydrochloride

This classification denotes a carbonic anhydrase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3J751V0284. European Medicines Agency schedules Mafenide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02999MIG. Mafenide hydrochloride generally arises in the molecular formula C7H10N2O2S.CLH. The term 'mafenide hydrochloride' is an International Nomenclature of Cosmetic Ingredients designation.

Most nations, for tariff and trade purposes, schedule mafenide hydrochloride under HS 29350090 and SITC 51580. As of Q4 2014, MAFENIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Mafenide hydrochloride bears US NLM identifiers UMLS ID C2698002 and NCI Concept Code C76107. SMILES: C1CC(CCC1CN)S(=O)(=O)N.CL.

UNSPSC 51283939 Mafenide hydrochloride is a Commodity code that nominally names a single pharmaceutical product, but recent state and local solicitations tagged with this code show little alignment with mafenide hydrochloride specifically. The recent opportunities instead span broader pharmaceutical and medical supply procurement — including naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, direct-to-manufacturer prescription programs, and fire department emergency medical supplies. The code appears to reflect either a data-entry error in the tagging process or a legacy classification that state and local procurement offices are applying to a wider range of pharmaceutical and medical commodity acquisitions than the code's nominal scope suggests. State and local issuing bodies purchasing under this code include county health departments, state health and human services commissions, municipal purchasing departments, and multistate cooperative purchasing alliances; Seminole County, Florida; the Texas Health and Human Services Commission; the City of Tampa; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration appear in recent activity.

Recent opportunities span Florida, Texas, Minnesota, and Oregon. The Minnesota MMCAP procurement (RFP S1070000015802, due March 26, 2026) sought multiple contracts for generic pharmaceuticals and OTC products from manufacturers, with products to be distributed through three authorized wholesalers to state and local government facilities across participating states. The City of Tampa issued an IFB (26P00145, due March 13, 2026) for 169 line items of medical and first aid supplies valued at $700,000.00 for the Tampa Fire Department Rescue Division, designated as a sheltered market opportunity with a 5 percent bid discount for certified Small Local Business Enterprises. Seminole County, Florida solicited naloxone and drug deactivation systems (IFB 60459723LAS, due July 26, 2023) on an annual basis for quarterly delivery to the county community health building. The Texas HHS Commission issued an RFI (HHS0017013, due April 3, 2026) to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The code shows sparse relevant recent activity; the nominal scope (mafenide hydrochloride, a topical burn-treatment pharmaceutical) does not clearly match the medical supply and pharmaceutical procurement patterns tagged to it.